DK2780027T3 - Apoaequorin for limiting ischemia-induced nerve damage. - Google Patents
Apoaequorin for limiting ischemia-induced nerve damage. Download PDFInfo
- Publication number
- DK2780027T3 DK2780027T3 DK12795955.9T DK12795955T DK2780027T3 DK 2780027 T3 DK2780027 T3 DK 2780027T3 DK 12795955 T DK12795955 T DK 12795955T DK 2780027 T3 DK2780027 T3 DK 2780027T3
- Authority
- DK
- Denmark
- Prior art keywords
- apoaequorin
- injection
- subject
- ischemia
- composition
- Prior art date
Links
- 108010041089 apoaequorin Proteins 0.000 title claims description 94
- 208000028389 Nerve injury Diseases 0.000 title claims 5
- 230000008764 nerve damage Effects 0.000 title claims 5
- 208000028867 ischemia Diseases 0.000 title description 12
- 239000007924 injection Substances 0.000 claims description 57
- 238000002347 injection Methods 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 46
- 210000002569 neuron Anatomy 0.000 claims description 22
- 201000006474 Brain Ischemia Diseases 0.000 claims description 13
- 210000005110 dorsal hippocampus Anatomy 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 238000002203 pretreatment Methods 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 230000008859 change Effects 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 102000003814 Interleukin-10 Human genes 0.000 description 15
- 108090000174 Interleukin-10 Proteins 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 14
- 229940076144 interleukin-10 Drugs 0.000 description 14
- 229920000858 Cyclodextrin Polymers 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- -1 olive oil Chemical class 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 230000000302 ischemic effect Effects 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 230000001537 neural effect Effects 0.000 description 10
- 230000000324 neuroprotective effect Effects 0.000 description 9
- 108010085238 Actins Proteins 0.000 description 8
- 102000007469 Actins Human genes 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000007911 parenteral administration Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 5
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000004112 neuroprotection Effects 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108010000239 Aequorin Proteins 0.000 description 4
- 102000016838 Calbindin 1 Human genes 0.000 description 4
- 108010028310 Calbindin 1 Proteins 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 230000002530 ischemic preconditioning effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101000794475 Schistosoma mansoni Calcium-binding protein Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 3
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WZMOWQCNPFDWPA-UHFFFAOYSA-N 2-fluoro-4-methyl-1-nitrobenzene Chemical compound CC1=CC=C([N+]([O-])=O)C(F)=C1 WZMOWQCNPFDWPA-UHFFFAOYSA-N 0.000 description 2
- XXFANTYPKDIONG-WJMYNTJYSA-N 6-o-α-d-glucosyl-β-cyclodextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@H]([C@H](O)[C@H]2O)O[C@@H](O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]3O[C@@H](O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]3O[C@@H](O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]3O[C@@H](O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]3O[C@@H](O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]3O[C@@H](O[C@@H]3CO)[C@H](O)[C@@H](O)[C@@H]3O[C@H]2O1 XXFANTYPKDIONG-WJMYNTJYSA-N 0.000 description 2
- 108010083590 Apoproteins Proteins 0.000 description 2
- 102000006410 Apoproteins Human genes 0.000 description 2
- 241000700108 Ctenophora <comb jellyfish phylum> Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XXFANTYPKDIONG-UHFFFAOYSA-N 6-O-alpha-D-glucosyl-beta-cyclodextrin Natural products OC1C(O)C(O)C(CO)OC1OCC1C(C(O)C2O)OC(OC3CO)C(O)C(O)C3OC(OC3CO)C(O)C(O)C3OC(OC3CO)C(O)C(O)C3OC(OC3CO)C(O)C(O)C3OC(OC3CO)C(O)C(O)C3OC(OC3CO)C(O)C(O)C3OC2O1 XXFANTYPKDIONG-UHFFFAOYSA-N 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108060005874 Parvalbumin Proteins 0.000 description 1
- 102000001675 Parvalbumin Human genes 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000010413 ischemic postconditioning Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000003982 neuronal uptake Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 210000005111 ventral hippocampus Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559816P | 2011-11-15 | 2011-11-15 | |
| PCT/US2012/065291 WO2013074798A1 (en) | 2011-11-15 | 2012-11-15 | Apoaequorin for reducing neuronal injury due to ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2780027T3 true DK2780027T3 (en) | 2017-09-25 |
Family
ID=47295186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12795955.9T DK2780027T3 (en) | 2011-11-15 | 2012-11-15 | Apoaequorin for limiting ischemia-induced nerve damage. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140294874A1 (enExample) |
| EP (1) | EP2780027B1 (enExample) |
| JP (1) | JP6181061B2 (enExample) |
| KR (1) | KR102009932B1 (enExample) |
| CN (1) | CN104244966B (enExample) |
| AU (1) | AU2012340446B2 (enExample) |
| BR (1) | BR112014011630A2 (enExample) |
| CA (1) | CA2855719C (enExample) |
| CY (1) | CY1119300T1 (enExample) |
| DK (1) | DK2780027T3 (enExample) |
| ES (1) | ES2643392T3 (enExample) |
| HR (1) | HRP20171532T1 (enExample) |
| HU (1) | HUE035017T2 (enExample) |
| IL (1) | IL232494B (enExample) |
| IN (1) | IN2014CN04009A (enExample) |
| LT (1) | LT2780027T (enExample) |
| MX (1) | MX350259B (enExample) |
| PL (1) | PL2780027T3 (enExample) |
| PT (1) | PT2780027T (enExample) |
| SG (1) | SG11201402364WA (enExample) |
| SI (1) | SI2780027T1 (enExample) |
| WO (1) | WO2013074798A1 (enExample) |
| ZA (1) | ZA201403577B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40959A (fr) * | 2014-11-11 | 2017-09-19 | Quincy Bioscience Llc | Compositions contenant de l'apoaéquorine et leurs procédés d'utilisation pour traiter l'inflammation neuronale |
| KR20180001229A (ko) | 2016-06-27 | 2018-01-04 | 삼성에스디아이 주식회사 | 이차 전지의 제조 방법 및 이를 이용한 이차 전지 |
| HUE067969T2 (hu) * | 2016-09-23 | 2024-12-28 | Quincy Bioscience Llc | Apoaequorint és D-vitamint tartalmazó készítmények és alkalmazási eljárásaik |
| RU2642961C1 (ru) * | 2017-02-21 | 2018-01-29 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемии головного мозга |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060229243A1 (en) * | 2004-06-21 | 2006-10-12 | Quincy Resource Group, Inc. | Aequorin-containing compositions and methods of using same |
| GB0602992D0 (en) * | 2006-02-15 | 2006-03-29 | Morvus Technology Ltd | Methods, genes and proteins |
| MX2010009753A (es) * | 2008-03-11 | 2010-09-30 | Quincy Bioscience Llc | Composiciones que contienen apoaecuorina y metodos de uso de las mismas. |
| WO2010017500A2 (en) * | 2008-08-08 | 2010-02-11 | Immunomedics, Inc. | Anti-pancreatic cancer antibodies |
| US20110130336A1 (en) * | 2009-10-16 | 2011-06-02 | Quincy Bioscience, Llc | Method of treating ischemic injury using apoaequorin |
-
2012
- 2012-11-15 SG SG11201402364WA patent/SG11201402364WA/en unknown
- 2012-11-15 PL PL12795955T patent/PL2780027T3/pl unknown
- 2012-11-15 ES ES12795955.9T patent/ES2643392T3/es active Active
- 2012-11-15 AU AU2012340446A patent/AU2012340446B2/en active Active
- 2012-11-15 HR HRP20171532TT patent/HRP20171532T1/hr unknown
- 2012-11-15 LT LTEP12795955.9T patent/LT2780027T/lt unknown
- 2012-11-15 BR BR112014011630A patent/BR112014011630A2/pt not_active Application Discontinuation
- 2012-11-15 MX MX2014005798A patent/MX350259B/es active IP Right Grant
- 2012-11-15 JP JP2014542463A patent/JP6181061B2/ja active Active
- 2012-11-15 US US14/358,274 patent/US20140294874A1/en not_active Abandoned
- 2012-11-15 IN IN4009CHN2014 patent/IN2014CN04009A/en unknown
- 2012-11-15 SI SI201231064T patent/SI2780027T1/sl unknown
- 2012-11-15 WO PCT/US2012/065291 patent/WO2013074798A1/en not_active Ceased
- 2012-11-15 EP EP12795955.9A patent/EP2780027B1/en active Active
- 2012-11-15 CA CA2855719A patent/CA2855719C/en active Active
- 2012-11-15 HU HUE12795955A patent/HUE035017T2/en unknown
- 2012-11-15 PT PT127959559T patent/PT2780027T/pt unknown
- 2012-11-15 CN CN201280066993.1A patent/CN104244966B/zh active Active
- 2012-11-15 DK DK12795955.9T patent/DK2780027T3/en active
- 2012-11-15 KR KR1020147016261A patent/KR102009932B1/ko active Active
-
2014
- 2014-05-07 IL IL232494A patent/IL232494B/en active IP Right Grant
- 2014-05-16 ZA ZA2014/03577A patent/ZA201403577B/en unknown
-
2017
- 2017-08-08 CY CY20171100851T patent/CY1119300T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014005798A (es) | 2014-05-30 |
| CN104244966B (zh) | 2019-01-11 |
| KR102009932B1 (ko) | 2019-08-12 |
| HUE035017T2 (en) | 2018-03-28 |
| CA2855719A1 (en) | 2013-05-23 |
| LT2780027T (lt) | 2017-10-25 |
| NZ624736A (en) | 2016-05-27 |
| KR20140097369A (ko) | 2014-08-06 |
| ES2643392T3 (es) | 2017-11-22 |
| ZA201403577B (en) | 2015-07-29 |
| AU2012340446B2 (en) | 2017-08-31 |
| IL232494B (en) | 2019-03-31 |
| PT2780027T (pt) | 2017-10-04 |
| BR112014011630A2 (pt) | 2017-06-27 |
| US20140294874A1 (en) | 2014-10-02 |
| WO2013074798A1 (en) | 2013-05-23 |
| CA2855719C (en) | 2021-10-26 |
| EP2780027A1 (en) | 2014-09-24 |
| PL2780027T3 (pl) | 2017-11-30 |
| CY1119300T1 (el) | 2018-02-14 |
| SG11201402364WA (en) | 2014-09-26 |
| IL232494A0 (en) | 2014-06-30 |
| JP6181061B2 (ja) | 2017-08-16 |
| JP2014533692A (ja) | 2014-12-15 |
| MX350259B (es) | 2017-08-31 |
| AU2012340446A1 (en) | 2014-05-29 |
| IN2014CN04009A (enExample) | 2015-10-23 |
| HRP20171532T1 (hr) | 2017-11-17 |
| SI2780027T1 (sl) | 2017-11-30 |
| CN104244966A (zh) | 2014-12-24 |
| HK1202417A1 (en) | 2015-10-02 |
| EP2780027B1 (en) | 2017-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vanhorebeek et al. | Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? | |
| Streijger et al. | Ketogenic diet improves forelimb motor function after spinal cord injury in rodents | |
| ES2985112T3 (es) | Composiciones y métodos de potenciación de antimicrobianos | |
| JP2022168118A (ja) | 関節を治療するための組成物及びキット | |
| EP2780027B1 (en) | Apoaequorin for reducing neuronal injury due to ischemia | |
| JP2025118608A (ja) | 軟骨細胞増殖を調節し、軟骨マトリックス産生を増加させるための組成物および方法 | |
| KR20210118883A (ko) | 레시니페라톡신을 투여하여 골관절염 통증을 치료하는 방법 | |
| US9387250B2 (en) | Therapeutic compositions for bone repair | |
| US11229626B2 (en) | Synergistic nutritional compositions for treating seizures and chronic inflammatory diseases | |
| KR101755360B1 (ko) | 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물 | |
| JP2014221735A (ja) | ショウガオール類を有効成分として含有する肝細胞活性化剤、並びに該肝細胞活性化剤を含有する固形製剤、液状製剤及び機能性食品 | |
| CA3031083A1 (en) | Uses of il-12 as a replacement immunotherapeutic | |
| CN1087278A (zh) | 溶菌酵素二聚体的新用途及其含有溶菌酵素二聚体的制剂 | |
| HK1202417B (en) | Apoaequorin for reducing neuronal injury due to ischemia | |
| WO2015084706A1 (en) | Intra-articular formulations and methods for treatment of osteoarthritis | |
| NZ624736B2 (en) | Apoaequorin for reducing neuronal injury due to ischemia | |
| US20110130336A1 (en) | Method of treating ischemic injury using apoaequorin | |
| US6720305B1 (en) | Injectable formulations containing ramoplanin | |
| KR20170072350A (ko) | 아포에쿼린-함유 조성물 및 이의 뉴런 염증을 치료하기 위한 사용 방법 | |
| US10765720B2 (en) | Composition for preventing or treating hyperoxia-induced lung injury comprising WKYMVm peptide as an active ingredient | |
| Caddy | Efficacy of veterinary antivirals in small animals | |
| Nessim et al. | Prophylactic effect of the anti-inflammatory drug diclofenac in experimental schistosomiasis mansoni | |
| KR20140104932A (ko) | 당뇨병성 창상의 예방 또는 치료용 약학 조성물 | |
| JP2011063522A (ja) | 活性安定化製剤 | |
| JP2014221734A (ja) | ジンゲロール類を有効成分として含有する肝細胞活性化剤、並びに該肝細胞活性化剤を含有する固形製剤、液状製剤及び機能性食品 |